![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FMNL1 |
Gene summary for FMNL1 |
![]() |
Gene information | Species | Human | Gene symbol | FMNL1 | Gene ID | 752 |
Gene name | formin like 1 | |
Gene Alias | C17orf1 | |
Cytomap | 17q21.31 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | O95466 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
752 | FMNL1 | male-WTA | Human | Thyroid | PTC | 5.43e-04 | 6.85e-02 | 0.1037 |
752 | FMNL1 | PTC05 | Human | Thyroid | PTC | 7.87e-03 | 2.41e-01 | 0.2065 |
752 | FMNL1 | PTC06 | Human | Thyroid | PTC | 1.12e-04 | 1.29e-01 | 0.2057 |
752 | FMNL1 | PTC07 | Human | Thyroid | PTC | 6.60e-09 | 1.37e-01 | 0.2044 |
752 | FMNL1 | ATC09 | Human | Thyroid | ATC | 1.19e-08 | 3.22e-01 | 0.2871 |
752 | FMNL1 | ATC11 | Human | Thyroid | ATC | 8.51e-03 | 3.22e-01 | 0.3386 |
752 | FMNL1 | ATC1 | Human | Thyroid | ATC | 4.18e-09 | 3.60e-01 | 0.2878 |
752 | FMNL1 | ATC2 | Human | Thyroid | ATC | 4.99e-14 | 1.10e+00 | 0.34 |
752 | FMNL1 | ATC3 | Human | Thyroid | ATC | 1.54e-04 | 3.39e-01 | 0.338 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0022604112 | Thyroid | PTC | regulation of cell morphogenesis | 165/5968 | 309/18723 | 2.60e-15 | 1.82e-13 | 165 |
GO:0008360111 | Thyroid | PTC | regulation of cell shape | 86/5968 | 154/18723 | 6.22e-10 | 1.95e-08 | 86 |
GO:0030865110 | Thyroid | PTC | cortical cytoskeleton organization | 38/5968 | 61/18723 | 9.77e-07 | 1.46e-05 | 38 |
GO:003086616 | Thyroid | PTC | cortical actin cytoskeleton organization | 25/5968 | 40/18723 | 6.51e-05 | 5.72e-04 | 25 |
GO:00510144 | Thyroid | PTC | actin filament severing | 10/5968 | 16/18723 | 1.13e-02 | 4.49e-02 | 10 |
GO:002260429 | Thyroid | ATC | regulation of cell morphogenesis | 171/6293 | 309/18723 | 2.36e-15 | 1.70e-13 | 171 |
GO:000836026 | Thyroid | ATC | regulation of cell shape | 91/6293 | 154/18723 | 7.33e-11 | 2.31e-09 | 91 |
GO:003086523 | Thyroid | ATC | cortical cytoskeleton organization | 41/6293 | 61/18723 | 8.28e-08 | 1.43e-06 | 41 |
GO:003086617 | Thyroid | ATC | cortical actin cytoskeleton organization | 28/6293 | 40/18723 | 2.77e-06 | 3.19e-05 | 28 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FMNL1 | SNV | Missense_Mutation | novel | c.1021N>C | p.Asn341His | p.N341H | O95466 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
FMNL1 | SNV | Missense_Mutation | novel | c.656N>A | p.Arg219His | p.R219H | O95466 | protein_coding | deleterious(0.01) | probably_damaging(0.984) | TCGA-B5-A5OC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD |
FMNL1 | SNV | Missense_Mutation | c.2937G>T | p.Lys979Asn | p.K979N | O95466 | protein_coding | deleterious(0) | probably_damaging(0.93) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
FMNL1 | SNV | Missense_Mutation | c.2928G>T | p.Glu976Asp | p.E976D | O95466 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FMNL1 | SNV | Missense_Mutation | c.3212T>C | p.Val1071Ala | p.V1071A | O95466 | protein_coding | tolerated(1) | benign(0.024) | TCGA-D1-A15X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FMNL1 | SNV | Missense_Mutation | c.728N>A | p.Gly243Asp | p.G243D | O95466 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D1-A177-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
FMNL1 | SNV | Missense_Mutation | rs370784492 | c.2120N>T | p.Ala707Val | p.A707V | O95466 | protein_coding | tolerated(1) | benign(0.024) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
FMNL1 | SNV | Missense_Mutation | novel | c.2956N>A | p.Phe986Ile | p.F986I | O95466 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
FMNL1 | SNV | Missense_Mutation | c.2667N>C | p.Glu889Asp | p.E889D | O95466 | protein_coding | tolerated(0.18) | benign(0.102) | TCGA-E6-A1LZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD | |
FMNL1 | SNV | Missense_Mutation | rs755479906 | c.2759N>A | p.Arg920His | p.R920H | O95466 | protein_coding | tolerated(0.21) | possibly_damaging(0.588) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |